Major R&D Pipeline
(As of May 15, 2024)
-
鈼�:Development progress from January 2024 onwards銆�鈼嬶細Development progress from April 2023 onwards
Neurology
Dementia
*You can scroll to the left or right here
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 銆孡eqembi銆�(lecanemab/BAN2401)銆�Treatment for Alzheimer’s disease / anti-Aβ protofibril antibody銆�In-license (BioArctic AB)銆�Injection銆�Joint development with Biogen Inc. | ||||
| 鈼� | Early Alzheimer’s disease | 301 (Clarity AD) | US | Traditional approval
(July 2023) |
| 鈼� | Japan | Approval (September 2023) | ||
| 鈼� | China | Approval (January 2024) | ||
| Europe | Submission
(accepted: January 2023) |
|||
| 鈼� | Asia (South Korea) | Submission
(June 2023) |
||
| 鈼� | IV maintenance dosing for early AD (Additional Dosage and Administration) | 201/301 | US | Submission (March 2024) |
| 鈼� | Maintenance dosing of a subcutaneous injection formulation for early AD (Additional Formulation) | 301 | US | Rolling Submission (initiated: May 2024) |
| Preclinical Alzheimer’s disease | 303 (AHEAD 3-45) | Japan/US/Europe | 笔鈪� | |
| E2814銆�anti-MTBR tau antibody銆�Collaboration (University College London)銆�Injection | ||||
| Alzheimer’s disease | Tau Nexgen | Japan/US/Europe | 笔鈪�/鈪� | |
| 103 | US/Europe | 笔鈪�/鈪� | ||
| E2511銆�Synapse regenerant銆�In-house銆�Oral | ||||
| Alzheimer’s disease | - | US | 笔鈪� | |
| 贰2025銆赌滨苍-丑辞耻蝉别銆赌滨苍箩别肠迟颈辞苍 | ||||
| Alzheimer’s disease | - | US | 笔鈪� | |
Neurological diseases other than dementia
*You can scroll to the left or right here
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 銆孎ycompa銆�(perampanel/E2007)銆�Antiepileptic agent / AMPA receptor antagonist銆�In-house銆�Oral / Injection | ||||
| 鈼� | Injection formulation (Additional Formulation) | - | Japan | Approval (January 2024) |
| 鈼� | Adjunctive therapy for primary generalized tonic-clonic seizures (Additional Indication) | 332 | China | Approval (April 2024) |
| 銆孌ayvigo銆�(lemborexant/E2006)銆�Insomnia treatment / Orexin receptor antagonist銆�In-house銆�Oral | ||||
| 鈼� | Insomnia disorder | 311 | China | Submission (accepted: January 2024) |
| mecobalamin/E0302)銆�Treatment for Amyotrophic lateral sclerosis (ALS)銆�In-house銆�Injection | ||||
| 鈼� | ALS | JETALS | Japan | Submission (January 2024) |
| lorcaserin/E2023銆�Treatment for Dravet syndrome / serotonin 2C receptor agonist銆�In-license (Arena Pharmaceuticals)銆�Oral | ||||
| Dravet syndrome | 304 | US | 笔鈪� | |
| 贰2086銆赌滨苍-丑辞耻蝉别銆赌翱谤补濒 | ||||
| Narcolepsy | - | US | 笔鈪� | |
| 贰础4017銆赌滨苍-丑辞耻蝉别銆赌翱谤补濒 | ||||
| Chemotherapy-induced peripheral neuropathy (Development conducted by EA Pharma) | - | Japan | 笔鈪� | |
Oncology
*You can scroll to the left or right here
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 銆孡envima/Kisplyx銆�(lenvatinib/E7080)銆�Anticancer agent / kinase inhibitor銆�In-house銆�Oral | ||||
| In combination with anti-PD-1 therapy pembrolizumab, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication) | ||||
| Hepatocellular carcinoma (in combination with transcatheter arterial chemoembolization) / First-line | LEAP-012 | Japan/US/Europe/China | 笔鈪� | |
| Esophageal carcinoma (in combination with chemotherapy) / First-line | LEAP-014 | Japan/US/Europe/China | 笔鈪� | |
| Gastric cancer (in combination with chemotherapy) / First-line | LEAP-015 | Japan/US/Europe/China | 笔鈪� | |
| Head and neck cancer / Second-line | LEAP-009 | US/Europe | 笔鈪� | |
| In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Indication) | ||||
| Hepatocellular carcinoma | - | Japan | 笔鈪� | |
| 銆孒alaven銆�(eribulin/E7389)銆�Anticancer agent / microtubule dynamics inhibitor銆�In-house銆�Injection | ||||
| Monotherapy (Additional Formulation) | ||||
| Liposomal formulation | - | Japan/Europe | 笔鈪� | |
| In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Formulation) | ||||
| Liposomal formulation | 120 | Japan | 笔鈪�/鈪� | |
| tasurgratinib/E7090銆�Anticancer agent / FGFR1, FGFR2, FGFR3 inhibitor銆�In-house銆�Oral | ||||
| 鈼� | Biliary tract cancer with FGFR2 gene fusion | 201 | Japan | Submission (December 2023) |
| Breast cancer | - | Japan | 笔鈪� | |
| farletuzumab ecteribulin锛團ZEC锛�/MORAb-202銆�Anticancer agent / Folate receptor α targeted antibody drug conjugate銆�In-house銆�Injection銆�Joint development with Bristol Myers Squibb | ||||
| Non-small cell lung cancer | 203 | US/Europe | 笔鈪� | |
| Ovarian cancer, peritoneal cancer, fallopian tube cancer | 205 | Japan/US/Europe | 笔鈪� | |
| Solid tumors | 201 | US/Europe | 笔鈪�/鈪� | |
| BB-1701銆�Anticancer agent / HER2 targeted antibody drug conjugate銆�In-house銆�Injection | ||||
| 鈼� | Breast cancer | 205 | JP/US | 笔鈪� |
| E7386銆�Anticancer agent / CBP/β-catenin interaction inhibitor銆�Collaboration (PRISM BioLab)銆�Oral | ||||
| Solid tumors (in combination with pembrolizumab) | 201 | Japan/US/Europe | 笔鈪�/鈪� | |
| Solid tumors | - | Japan/US/Europe | 笔鈪� | |
| Solid tumors (in combination with lenvatinib) | - | Japan/US/Europe | 笔鈪� | |
| H3B-6545銆�Anticancer agent / ERα inhibitor銆�In-house銆�Oral | ||||
| Breast cancer (in combination with CDK4/6 inhibitor palbociclib) | - | US/Europe | 笔鈪� | |
| E7130銆�Collaboration (Harvard University)銆�Injection | ||||
| Solid tumors | - | Japan | 笔鈪� | |
| 贰7766銆赌滨苍-丑辞耻蝉别銆赌滨苍箩别肠迟颈辞苍 | ||||
| Solid tumors | - | US/Europe | 笔鈪� | |
Global Health
*You can scroll to the left or right here
| Disease | Sponsor of study | Region | Development Stage | |
|---|---|---|---|---|
| fosravuconazole/E1224銆�Antifungal agent / ergosterol synthesis inhibitor銆�In-house銆�Oral | ||||
| Eumycetoma
*Supported by GHIT fund *麻豆果冻传媒 is mainly responsible for non-clinical studies and the provision of the investigational drug. |
DNDi銉籑ycetoma Research Center of the University of Khartoum | Sudan | 笔鈪/鈪� | |
| SJ733銆�Antimalarial agent / ATP4 inhibitor銆�Co-development (University of Kentucky)銆�Oral | ||||
| Malaria
*Supported by GHIT fund *麻豆果冻传媒 is responsible for the provision of drug substance and formulation manufacturing |
University of Kentucky | Peru | 笔鈪� | |
| AWZ1066S銆�Antifilarial agent / antiwolbachia mechanism Co-development (Liverpool School of Tropical Medicine)銆�Oral | ||||
| Lymphatic filariasis
*Supported by the GHIT Fund and Medical Research Council in the UK *麻豆果冻传媒 is responsible for the provision of drug substance and formulation manufacturing |
Liverpool School of Tropical Medicine | UK | 笔鈪� | |
Gastrointestinal Disorders
*You can scroll to the left or right here
| Disease | Study | Region | Development stage | |
|---|---|---|---|---|
| MOVICOL/(AJG555)銆�Chronic constipation treatment / polyethylene glycol preparation銆�In-license (Norgine)銆�Oral | ||||
| 鈼� | Chronic constipation in children under 2 years of age (Additional Dosage and Administration)銆�(Development conducted by EA Pharma) | CT3 | Japan | 笔鈪� |
| 础闯惭347銆赌滨苍-丑辞耻蝉别銆赌翱谤补濒 | ||||
| Inflammatory bowel disease (Development conducted by EA Pharma) | - | Europe | 笔鈪� | |
| 贰础1080銆赌滨苍-丑辞耻蝉别銆赌翱谤补濒 | ||||
| Inflammatory bowel disease (Development conducted by EA Pharma) | - | Europe | 笔鈪� | |
| 贰础3571銆赌滨苍-丑辞耻蝉别銆赌翱谤补濒 | ||||
| Metabolic dysfunction-associated steatohepatitis (Development conducted by EA Pharma) | - | Japan | 笔鈪� | |
Other
*You can scroll to the left or right here
| Disease | Study | Region | Development stage | |
|---|---|---|---|---|
| dotinurad / FYU-981銆�Treatment for Hyperuricemia and Gout / selective URAT1 inhibitor銆�In-license (FUJI YAKUHIN)銆�Oral | ||||
| 鈼� | Gout, hyperuricemia | - | Asia (Philippines) | Submission (September 2023) |
| 鈼� | Gout | 301 | China |
Submission (accepted: January 2024) |
| E6742銆�Treatment for Systemic lupus erythematosus / TLR 7/8 inhibitor銆�In-house銆�Oral | ||||
| Systemic lupus erythematosus | 101 | Japan | 笔鈪�/鈪� | |
| E8001銆�In house銆�Injection | ||||
| Rejection reaction associated with organ transplantation | - | Japan | 笔鈪� | |